New Trends in Molecular and Cellular Biomarker Discovery for Colorectal Cancer

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2016 Jul 20

PMID 27433083

Citations 37

Authors

Parisa Aghagolzadeh

Ramin Radpour

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer (CRC) is the third leading cause of cancer death worldwide, which is consequence of multistep tumorigenesis of several genetic and epigenetic events. Since CRC is mostly asymptomatic until it progresses to advanced stages, the early detection using effective screening approaches, selection of appropriate therapeutic strategies and efficient follow-up programs are essential to reduce CRC mortalities. Biomarker discovery for CRC based on the personalized genotype and clinical information could facilitate the classification of patients with certain types and stages of cancer to tailor preventive and therapeutic approaches. These cancer-related biomarkers should be highly sensitive and specific in a wide range of specimen(s) (including tumor tissues, patients' fluids or stool). Reliable biomarkers which enable the early detection of CRC, can improve early diagnosis, prognosis, treatment response prediction, and recurrence risk. Advances in our understanding of the natural history of CRC have led to the development of different CRC associated molecular and cellular biomarkers. This review highlights the new trends and approaches in CRC biomarker discovery, which could be potentially used for early diagnosis, development of new therapeutic approaches and follow-up of patients.

Citing Articles

Narrative review of neoadjuvant therapy in patients with locally advanced colon cancer.

Chuang J, Chen Y, Wang J Kaohsiung J Med Sci. 2024; 41(2):e12926.

PMID: 39717937 PMC: 11827549. DOI: 10.1002/kjm2.12926.

Inorganic nanoparticle-based treatment approaches for colorectal cancer: recent advancements and challenges.

Narayana S, Gowda B, Hani U, Shimu S, Paul K, Das A J Nanobiotechnology. 2024; 22(1):427.

PMID: 39030546 PMC: 11264527. DOI: 10.1186/s12951-024-02701-3.

Enhancement of Acetate-Induced Apoptosis of Colorectal Cancer Cells by Cathepsin D Inhibition Depends on Oligomycin A-Sensitive Respiration.

Alves S, Santos-Pereira C, Oliveira C, Preto A, Chaves S, Corte-Real M Biomolecules. 2024; 14(4).

PMID: 38672489 PMC: 11048611. DOI: 10.3390/biom14040473.

Circulating Nucleic Acids in Colorectal Cancer: Diagnostic and Prognostic Value.

Igder S, Zamani M, Fakher S, Siri M, Ashktorab H, Azarpira N Dis Markers. 2024; 2024:9943412.

PMID: 38380073 PMC: 10878755. DOI: 10.1155/2024/9943412.

[Construction of a fecal protein Luminex liquid chip detection system for early diagnosis of colorectal tumors].

Li J, Yin L, Zhang M, Xia Y, Zuo L, Liu M Nan Fang Yi Ke Da Xue Xue Bao. 2023; 43(11):1874-1880.

PMID: 38081604 PMC: 10713475. DOI: 10.12122/j.issn.1673-4254.2023.11.06.

References

Barekati Z, Radpour R, Kohler C, Zhang B, Toniolo P, Lenner P . Methylation profile of TP53 regulatory pathway and mtDNA alterations in breast cancer patients lacking TP53 mutations. Hum Mol Genet. 2010; 19(15):2936-46. DOI: 10.1093/hmg/ddq199. View

Fransen K, Klintenas M, Osterstrom A, Dimberg J, Monstein H, Soderkvist P . Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis. 2003; 25(4):527-33. DOI: 10.1093/carcin/bgh049. View

Feinberg A, Tycko B . The history of cancer epigenetics. Nat Rev Cancer. 2004; 4(2):143-53. DOI: 10.1038/nrc1279. View

Leslie A, Carey F, Pratt N, Steele R . The colorectal adenoma-carcinoma sequence. Br J Surg. 2002; 89(7):845-60. DOI: 10.1046/j.1365-2168.2002.02120.x. View

Ramsahoye B, Biniszkiewicz D, Lyko F, Clark V, Bird A, Jaenisch R . Non-CpG methylation is prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a. Proc Natl Acad Sci U S A. 2000; 97(10):5237-42. PMC: 25812. DOI: 10.1073/pnas.97.10.5237. View

Hundt S, Haug U, Brenner H . Blood markers for early detection of colorectal cancer: a systematic review. Cancer Epidemiol Biomarkers Prev. 2007; 16(10):1935-53. DOI: 10.1158/1055-9965.EPI-06-0994. View

Harley C . Telomerase and cancer therapeutics. Nat Rev Cancer. 2008; 8(3):167-79. DOI: 10.1038/nrc2275. View

Kopetz S, Chang G, Overman M, Eng C, Sargent D, Larson D . Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009; 27(22):3677-83. PMC: 2720081. DOI: 10.1200/JCO.2008.20.5278. View

Radpour R, Barekati Z, Kohler C, Schumacher M, Grussenmeyer T, Jenoe P . Integrated epigenetics of human breast cancer: synoptic investigation of targeted genes, microRNAs and proteins upon demethylation treatment. PLoS One. 2011; 6(11):e27355. PMC: 3208622. DOI: 10.1371/journal.pone.0027355. View

10.

Heaphy C, Baumgartner K, Bisoffi M, Baumgartner R, Griffith J . Telomere DNA content predicts breast cancer-free survival interval. Clin Cancer Res. 2007; 13(23):7037-43. DOI: 10.1158/1078-0432.CCR-07-0432. View

11.

Li H, Myeroff L, Smiraglia D, Romero M, Pretlow T, Kasturi L . SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. Proc Natl Acad Sci U S A. 2003; 100(14):8412-7. PMC: 166243. DOI: 10.1073/pnas.1430846100. View

12.

Tsai H, Lin C, Huang C, Yang I, Yeh Y, Hsu W . Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients. Int J Clin Exp Pathol. 2015; 8(2):1900-10. PMC: 4396259. View

13.

Schetter A, Leung S, Sohn J, Zanetti K, Bowman E, Yanaihara N . MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 2008; 299(4):425-36. PMC: 2614237. DOI: 10.1001/jama.299.4.425. View

14.

Craven B, Zaric V, Martin A, Mureau C, Egan L . Effect of genetic deletion or pharmacological antagonism of tumor necrosis factor alpha on colitis-associated carcinogenesis in mice. Inflamm Bowel Dis. 2015; 21(3):485-95. DOI: 10.1097/MIB.0000000000000303. View

15.

Ogino S, Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Kirkner G . LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Int J Cancer. 2008; 122(12):2767-73. PMC: 2630175. DOI: 10.1002/ijc.23470. View

16.

WARD R, Meagher A, Tomlinson I, OConnor T, Norrie M, Wu R . Microsatellite instability and the clinicopathological features of sporadic colorectal cancer. Gut. 2001; 48(6):821-9. PMC: 1728324. DOI: 10.1136/gut.48.6.821. View

17.

Duffy M . Personalized treatment for patients with colorectal cancer: role of biomarkers. Biomark Med. 2015; 9(4):337-47. DOI: 10.2217/bmm.15.3. View

18.

Santini D, Loupakis F, Vincenzi B, Floriani I, Stasi I, Canestrari E . High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist. 2008; 13(12):1270-5. DOI: 10.1634/theoncologist.2008-0181. View

19.

Pu X, Huang G, Guo H, Guo C, Li H, Ye S . Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol. 2010; 25(10):1674-80. DOI: 10.1111/j.1440-1746.2010.06417.x. View

20.

Utting M, Werner W, Dahse R, Schubert J, Junker K . Microsatellite analysis of free tumor DNA in urine, serum, and plasma of patients: a minimally invasive method for the detection of bladder cancer. Clin Cancer Res. 2002; 8(1):35-40. View